Bond Biosciences

Bond Biosciences, Inc. is a private biopharmaceutical company focused on the discovery and development of first-in-class, non-absorbed oral therapies that harness locally excessive ions in the gastrointestinal (GI) tract to treat or prevent human diseases. The company’s portfolio includes its lead candidate BBI-001, as well as other non-absorbed therapies in the research stage.